Currently approved multiple sclerosis (MS) treatments mainly target the peripheral immune system, thereby reducing relapse rates and MRI markers of inflammation. A recent phase III trial indicates that laquinimod, a new orally active immunomodulator, has a CNS-intrinsic mode of action that is independent of effects on the peripheral immune response.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Brück, W. et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol. http://dx.doi.org/10.1001/jamaneurol.2013.3510.
Comi, G. et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N. Engl. J. Med. 366, 1000–1009 (2012).
Filippi, M. et al. Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. J. Neurol. Neurosurg. Psychiatry http://dx.doi.org/10.1136/jnnp-2013-306132.
Brück, W. et al. Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol. 124, 411–424 (2012).
Jolivel, V. et al. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis. Brain 136, 1048–1066 (2013).
Schulze-Topphoff, U. et al. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. PLoS ONE 7, e33797 (2012).
Brück, W. & Zamvil, S. S. Laquinimod, a once-daily oral drug in development for the treatment of relapsing–remitting multiple sclerosis. Expert Rev. Clin. Pharmacol. 5, 245–256 (2012).
Lassmann, H. Pathology and disease mechanisms in different stages of multiple sclerosis. J. Neurol. Sci. 333, 1–4 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W. Brück receives research support from Teva Pharmaceutical Industries, Biogen Idec, Genzyme and Novartis. He is a member of the scientific advisory boards of Teva Pharmaceutical Industries, Biogen Idec, Novartis and Genzyme/Sanofi, and serves on speaker's bureaus for Bayer Vital, Biogen Idec, Merck Serono, Teva Pharmaceutical Industries Ltd., Genzyme/Sanofi and Novartis. T. Vollmer has acted as a consultant for Teva Pharmaceutical Industries, Biogen Idec, Xenoport, Krog & Partners, Novartis Pharmaceuticals, Acorda, Mylan Pharmaceuticals, Hoffman-LaRoche. He has received research support from Janssen-Sergeant Pharmaceuticals, Medimmune, Vaccinex, ONO, Teva Neuroscience, Genzyme, Biogen Idec, Avinir, Acorda and Novartis.
Rights and permissions
About this article
Cite this article
Brück, W., Vollmer, T. Oral laquinimod for MS—bringing the brain into focus. Nat Rev Neurol 9, 664–665 (2013). https://doi.org/10.1038/nrneurol.2013.234
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2013.234
This article is cited by
-
Role and therapeutic value of dendritic cells in central nervous system autoimmunity
Cell Death & Differentiation (2015)